Trials / Completed
CompletedNCT02155647
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab | Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs. |
Timeline
- Start date
- 2014-07-03
- Primary completion
- 2019-05-02
- Completion
- 2023-05-03
- First posted
- 2014-06-04
- Last updated
- 2024-03-13
- Results posted
- 2020-07-22
Locations
61 sites across 7 countries: United States, Australia, France, Germany, Italy, Japan, Spain
Source: ClinicalTrials.gov record NCT02155647. Inclusion in this directory is not an endorsement.